StemCell Therapy

IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being positively advanced.

Read the original here:
NYMOX Updates Shareholders

PRESS RELEASE

See more here:
Notice of extraordinary general meeting in Saniona AB

COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.

Read the rest here:
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary resignation of Dr. Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director, effective as of August 1, 2022. Dr. Shailubhai resigned for personal reasons, and his resignation is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Read more:
Tiziana Life Sciences Announces Resignation of CEO

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the proposed consolidation of the Company’s shares (the “Share Consolidation”) was approved at its reconvened annual meeting of shareholders (the “Meeting”) held today.

Read the original here:
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

VANCOUVER, British Columbia, July 15, 2022 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF) (FRA: PU30), a growth-oriented and diversified company focused on the international cannabis industry, announces the resignation of Brian O’Neill as Director of the Company, effective immediately. The Company would like to thank Mr. O’Neill for his time and service to AGRA and wish him well with his future endeavours.

Read more:
Agra Ventures Announces Resignation of Brian O’Neill as Director

Precision medicine, sometimes known as "personalized medicine" is an innovative approach to tailoring disease prevention and treatment based on the individuals unique characteristics and genetic make-up. Precision medicine software provides the healthcare and life sciences community with integrated data and data-driven insights to strengthen their precision medicine program.

Move from the Traditional One-Size-Fits-All Approach to Personalized Care Approach

The precision medicine approach promises better clinical outcomes, safer medicines, and less wastage/cost savings. With the increasing demand to provide value to healthcare systems, drug developers have started to move away from the traditional one-size-fits-all approach to the personalized care approach.

Favorable Government Initiatives is Driving the Precision Medicine Software Market

Realizing the long-term benefits of personalized care in improving population health and reducing healthcare costs, governments across the world are supporting advanced treatments like precision medicine through initiatives, regulatory changes, and/or funding research.

For instance, in US, The Oncology Care Model, a specialty payment and delivery model developed by the CMS Innovation Center is providing incentives that have led to a surge of large community provider networks implementing precision medicine initiatives.

Some of the other programs to advance the research/use of precision medicine include The Precision Medicine Initiative (PMI), All of Us Research Program, precision FDA, and Million Veteran Program. In addition, FDA issued seven guidance documents in 2020 related to precision medicine. All these efforts would eventually boost the demand for precision medicine software.

Upcoming Growth Opportunities in Oncology

Precision medicine holds a tremendous promise for reshaping the way cancer is treated. The growing prevalence of cancer and increasing funding for cancer research would propel the adoption of precision medicine in oncology. High-quality patient datasets are the foundation to bring precision oncology into clinical practice. Thus, providing great opportunities for precision oncology software providers.

Rising Market Challenges: Precision Medicine Software Market

For the emergence of precision medicine in every medical sector, the medical industry needs to know how to optimize the utilization of big data with the increase in the amount of genomics, health, and lifestyle information.

Further, the high costs of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the shortage of expert technicians/bioinformaticians are some of the key challenges faced by this market players.

Competitive Landscape Analysis: Precision Medicine Software Market

The global precision medicine software market is highly competitive and fragmented. Some of the leading and emerging players operating in the global precision medicine software market are Syapse, Fabric Genomics, Sophia Genetics, 2bprecise, PierianDx, PhenoTips, Foundation Medicine, GenomOncology, Translational Software, LifeOmic Health, Sunquest Information Systems, Tempus, Human Longevity and N-of-One Inc.

Explore Detailed Market Research Insights on Precision Medicine Software Market @ https://meditechinsights.com/precision-medicine-software-market/

Visit link:
Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World

LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Companys research report on the single-cell analysis market, the growing focus on personalized medicine across the globe is contributing to the growth of the single-cell analysis market. Personalized medicine is a medical practice that uses the genetic profile of a particular individual to make decisions for the treatment of a disease and also for the prevention and diagnosis of the disease for that specific individual. The single-cell analysis could help in the treatment of various diseases by giving deep insights into the needs of individual patients, the nature of the disease, and the personalized treatment for them. Thus, more patients are opting for personalized medicine for themselves. For example, according to the survey conducted in July 2021, by Dosis, a dosing platform provider, of 1,000 people, 85% of patients think that personalized medicine will improve care for them and 80% of patients think that personalized medicine should be available for all. Hence, the increasing focus on personalized medicine is supporting the growth of the market.

Request for a sample of the global single-cell analysis market report

The global single-cell analysis market size is expected to grow from $2.58 billion in 2021 to $2.9 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The single-cell analysis industry growth is expected to reach $4.9 billion in 2026 at a CAGR of 14.1%.

Companies in the single-cell analysis market are focusing on technological advancements to deliver intact and viable single cells. With the help of technological advancements, companies in the market are maintaining sample integrity through shipping, storage, and processing, increasing the recovery rates of delicate cells and also eliminating the need for specialized instruments. For example, in October 2021, PerkinElmer, a US-based company engaged in diagnostics, food, environmental and industrial testing, and life science research, along with Honeycomb Biotechnologies, a US-based company involved in single-cell genomic analysis, launched HIVE scRNAseq solution, which is a portable, single-use, and handheld device that allows gentle capture, robust storage, and ease of processing for the analysis of single-cell samples. It has RNA-Seq libraries from a variety of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes, and neurons. The HIVE system is simple to use and offers potential for laboratories conducting fundamental, translational, clinical, and preclinical research.

Major players in the single-cell analysis market are Becton, Dickinson and Company, Merck KGAA, QIAGEN N.V., Thermo Fisher Scientific Inc., Illumina Inc., Fluidigm Corporation, 10X Genomics, Bio-Rad Laboratories, Novogene Corporation, Agilent Technologies Inc., Sartorius AG, Luminex Corporation, Fluxion Biosciences, and Oxford Nanopore Technologies.

The global single-cell analysis market analysis is segmented by product into consumables, instruments; by workflow into single-cell isolation and library preparation, downstream analysis, data analysis; by technique into flow cytometry, next generation sequencing, Polymerase Chain Reaction (PCR), microscopy, mass spectrometry, others; by application into cancer, immunology, neurology, stem cell, non-invasive prenatal diagnosis, in-vitro fertilization, others; by end-user into academic and research laboratories, biotechnology and pharmaceutical companies, hospital and diagnostic laboratories.

North America was the largest region in the single-cell analysis market in 2021. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in TBRCs single-cell analysis market outlook are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Single-Cell Analysis Global Market Report 2022 Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provide single-cell analysis market overviews, single-cell analysis market analyze and forecast market size and growth for the whole market, single-cell analysis market segments and geographies, single-cell analysis market trends, single-cell analysis market drivers, single-cell analysis market restraints, leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Not the market you are looking for? Check out some similar market intelligence reports:

Metabolomics Global Market Report 2022 By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors Of Metabolism), By Metabolomics Instruments (Separation Techniques, Detection Techniques), By Metabolomics Bioinformatics Tools & Services (Bioinformatics Tools And Database, Bioinformatics Services) Market Size, Trends, And Global Forecast 2022-2026

Cancer Tumor Profiling Global Market Report 2022 By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray), By Process Type (Genomics, Proteomics, Epigenetics, Metabolomics), By Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications) Market Size, Trends, And Global Forecast 2022-2026

Flow Cytometry Global Market Report 2022 By Type (Instruments, Reagents & Consumables, Software, Accessories, Services), By Technology (Cell-Based, Bead-Based), By End User (Hospitals And Clinics, Academia And Research Institutes, Pharmaceutical And Biotechnology Companies), By Application (Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Haematology) Market Size, Trends, And Global Forecast 2022-2026

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Link:
The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's...

Northwell Health, New York largest health care provider, and Google Cloud partner to improve patient care.

"Digital transformation is critical to our long-term goals of further advancing clinical excellence in our health system," said Michael Dowling, president and CEO, Northwell Health. "This partnership will help us deliver personalized experiences by safely and privately harnessing customers' data to enhance care, well-being, and equity in care for our patients."

As part of this partnership, Northwell Health will leverage Google Cloud as its preferred cloud platform for infrastructure modernization, and to build an interoperable data platform with AI and ML capabilities. This includes contextual recommendations that equip nurses and clinicians with decision making support that goes beyond summarizing the information from different records, building relationships between the information to help support the right actions at the right time.

"People want the same kind of seamless experiences and access to their healthcare that they have in other areas of their life, and healthcare providers need to meet these demands while also running the organization more efficiently," said Joe Miles, managing director, Global Healthcare & Life Sciences Solutions for Google Cloud. "Northwell Health is taking the lead on innovation and interoperability to transform health and wellness for millions of New Yorkers."

Privacy and security will be of the utmost importance in all aspects of this digital transformation. Through the implementation of Google Cloud's reliable infrastructure along with Northwell Health's layers of security, privacy controls and processes, the access and use of patient data will be appropriately protected.

AboutNorthwellHealth

Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 80,000 employees 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners are working to change health care for the better.We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionalsat the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and theHofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visitNorthwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

About Google Cloud

Google Cloud accelerates every organization's ability to digitally transform its business. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.

SOURCE Google Cloud

Excerpt from:
Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire

Dublin, July 15, 2022 (GLOBE NEWSWIRE) -- The "Global Microtome Market (2022-2027) by Product, Application, End User, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Microtome Market is estimated to be USD 449 Bn in 2022 and is projected to reach USD 596.34 Bn by 2027, growing at a CAGR of 5.84%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Microtome Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Microtome Market is segmented based on Product, Application, End Userand Geography.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are AGD Biomedicals, Amos Scientific, Boeckeler Instruments, Bright Instruments, etc.

Countries Studied

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

Why buy this report?

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics4.1 Drivers4.1.1 Increasing Consumer Awareness of Early Disease Diagnosis 4.1.2 Growth in Incidence of Chronic Diseases such as Cancer 4.1.3 Increasing Geriatric Population Coupled with Increasing Healthcare Expenditure4.2 Restraints4.2.1 Lack of Skilled Expertise and Unfavorable Reimbursement Policies4.3 Opportunities4.3.1 Increasing Demand for Personalized Medicine 4.3.2 Emerging Introduction of Technologically Advanced Diagnostic Equipment and Pathological Systems4.4 Challenges4.4.1 Reduced Adoption Rate in Under-developed and Developing Economies

5 Market Analysis5.1 Regulatory Scenario5.2 Porter's Five Forces Analysis5.3 Impact of COVID-195.4 Ansoff Matrix Analysis

6 Global Microtome Market, By Product6.1 Introduction6.2 Microtome Instruments 6.2.1 Rotary Microtomes 6.2.2 Cryostat Microtomes 6.2.3 Vibrating Microtomes 6.2.4 Other Microtomes 6.3 Microtome Accessories 6.3.1 Microtome Blades 6.3.2 Other Microtome Accessories 6.4 Technology 6.5 Manual Microtomes 6.6 Semi-Automated Microtomes 6.7 Fully Automated Microtomes

7 Global Microtome Market, By Application7.1 Introduction7.2 Disease Diagnosis 7.3 Medical Research

8 Global Microtome Market, By End User8.1 Introduction8.2 Hospital Laboratories 8.3 Clinical Laboratories 8.4 Other End Users

9 Americas' Microtome Market9.1 Introduction9.2 Argentina9.3 Brazil9.4 Canada9.5 Chile9.6 Colombia9.7 Mexico9.8 Peru9.9 United States9.10 Rest of Americas

10 Europe's Microtome Market10.1 Introduction10.2 Austria10.3 Belgium10.4 Denmark10.5 Finland10.6 France10.7 Germany10.8 Italy10.9 Netherlands10.10 Norway10.11 Poland10.12 Russia10.13 Spain10.14 Sweden10.15 Switzerland10.16 United Kingdom10.17 Rest of Europe

11 Middle East and Africa's Microtome Market11.1 Introduction11.2 Egypt11.3 Israel11.4 Qatar11.5 Saudi Arabia11.6 South Africa11.7 United Arab Emirates11.8 Rest of MEA

12 APAC's Microtome Market12.1 Introduction12.2 Australia12.3 Bangladesh12.4 China12.5 India12.6 Indonesia12.7 Japan12.8 Malaysia12.9 Philippines12.10 Singapore12.11 South Korea12.12 Sri Lanka12.13 Thailand12.14 Taiwan12.15 Rest of Asia-Pacific

13 Competitive Landscape13.1 Competitive Quadrant13.2 Market Share Analysis13.3 Strategic Initiatives13.3.1 M&A and Investments13.3.2 Partnerships and Collaborations13.3.3 Product Developments and Improvements

14 Company Profiles14.1 AGD Biomedicals 14.2 Amos Scientific14.3 Boeckeler Instruments14.4 Bright Instruments14.5 Campden Instruments 14.6 Cardinal Health14.7 Danaher 14.8 Diapath 14.9 Histo-Line Laboratories14.10 Jinhua YIDI Medical Appliance14.11 Laboid International14.12 Lafayette Instrument 14.13 Medimeas14.14 Medite Medical14.15 Microtec Laborgerate14.16 Milestone Medical14.17 RWD Life Science14.18 Sakura Finetek 14.19 Shenzhen Dakewei Biotechnology14.20 SLEE Medical14.21 SM Scientific Instruments14.22 Ted Pella

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4xhy15

See the article here:
Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga

New Approaches Needed To Support Digitization Of Healthcare

At the recent HIMSS conference in Helsinki, the breadth of digital solutions promising to transform healthcare was prodigious. What is also sadly evident for any seasoned observer of the sector is that the pace of change remains incredibly slow, and while digital tools have enabled many sectors to do more with less, healthcare remains largely beholden to Baumol's cost disease.

A recent project from the University of Twente suggests that for healthcare to truly achieve the benefits of digitization will require a different approach to transformation.

Digitization is about more than just the use of technology above all, its about a different way of working, and that requires vision, guts and leadership, the researchers explain.

The promises of digital healthcare are considerable, from the delivery of personalized medicine to a reduction in workload via a more preventative approach to healthcare that could also keep a lid on costs that are continuously escalating. As I argue in another article, the capacity to absorb new technologies is often a limiting factor in a sector that is nearly always stretched to breaking point, even before the pandemic exacerbated matters.

The researchers explored both the research literature and practice to try and identify ways to improve matters and accelerate the digitization of the sector. Central to their recommendations is a more proactive role from the government in driving digitization, with long-term policies needed to help set in motion the process of change. Fundamental to this is a shift in how people in the healthcare sector work.

One thing that needs to change is how we use personnel, the researchers explain. In addition to medical professionals, we must use professionals with a technical-medical background and data analysts.

The researchers argue that a key starting point is for healthcare organizations not to consider digitization as primarily a means of reducing costs. At the moment, they believe that healthcare organizations struggle to justify investing in digitization because it's not clear how they can recoup their costs. This then helps to undermine any willingness to experiment and innovate.

There are also considerable problems in terms of interoperability as few systems seem to work together or indeed exchange information effectively. The adoption of electronic patient records has been a well-known example of a digitization process beset by problems getting systems to talk to one another. Often the fragmented nature of healthcare systems means that each organization goes its own way, which hampers interoperability further.

"The entire global healthcare system had a rude awakening during the pandemic as without interoperability and definitions of data, our ability to collect information and exchange it during the early days of the pandemic was limited," Hal Woolf, President & CEO, HIMSS, explains. "Now we're in a place where people are recognizing the transactional nature of information as a critical dependecy in order for us to be able to look at public health and understand what is transpiring."

The Dutch researchers argue that for things to change, it's vital that the government take charge, as currently there is too large a gap between what government wants and what happens in practice. They believe that a multidisciplinary approach is vital for this gap to be narrowed and digitization supported.

Only by doing this do they believe that things like privacy, security, and inclusiveness can be properly addressed, with these obviously crucial for technologies like AI to make an impact. This could also help in terms of informing citizens of not only the possibilities with the digitization of healthcare but also their rights.

"It's critical that healthcare systems are able to dedicate some level of resources for the implementation of innovations, which should be somewhere between 2 and 5%," Woolf continues. "This is undoutedly a lot, but it sets aside the bandwidth for implementation and establishes a cadence in anticipation of the ongoing nature of change and innovation."

The Dutch team believes that by combining policy, infrastructure, funding, and government power then the digitization of healthcare can occur, with the aim being to ensure that technology is effectively used to ensure that healthcare is not only faster and more efficient but also that continuity and quality of care is maintained.

The pandemic showed us that many obstacles on the road towards digital care could be overcome in a short period of time," the researchers conclude. But still, the implementation of many digital applications is lagging behind. We need a change in culture, digital literacy training, and better long-term funding to ensure that digitization has a lasting impact on healthcare.

Read this article:
New Approaches Needed To Support Digitization Of Healthcare - Forbes

Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155163 (2000).

CAS PubMed Article Google Scholar

Suzuki, K. et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand. J. Rheumatol. 32, 197204 (2003).

CAS PubMed Article Google Scholar

Mishima, S. et al. Higher PGD(2) production by synovial mast cells from rheumatoid arthritis patients compared with osteoarthritis patients via miR-199a-3p/prostaglandin synthetase 2 axis. Sci. Rep. 11, 5738 (2021).

ADS CAS PubMed PubMed Central Article Google Scholar

McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429442 (2007).

CAS PubMed Article Google Scholar

Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244279 (2008).

CAS PubMed Article Google Scholar

Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 23382348 (2017).

PubMed Article Google Scholar

Weinblatt, M. E. Methotrexate in rheumatoid arthritis: A quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 16 (2013).

PubMed PubMed Central Google Scholar

Dey, M., Zhao, S. S. & Moots, R. J. Anti-TNF biosimilars in rheumatology: The end of an era?. Expert Opin. Biol. Ther. 21, 2936 (2021).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685699 (2020).

CAS PubMed Article Google Scholar

Garca, C. C., Lefvre, A. & Busnel, J.-M.R. Development of a flow cytometry-based functional assay to study anti-TNF mechanisms of action and capture donor heterogeneity. ImmunoHorizons 4, 648658 (2020).

PubMed Article CAS Google Scholar

Laffon, A. et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88, 546552 (1991).

CAS PubMed PubMed Central Article Google Scholar

Murata, K. et al. CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int. Immunol. 15, 987992 (2003).

CAS PubMed Article Google Scholar

Capsoni, F. et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res. Ther. 7, 208 (2005).

CAS PubMed PubMed Central Article Google Scholar

Leite Pereira, A. et al. Characterization of phenotypes and functional activities of leukocytes from rheumatoid arthritis patients by mass cytometry. Front. Immunol. 0, 2384 (2019).

Article CAS Google Scholar

Lin, S.-J. et al. Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15. Sci. Rep. 2020(10), 18 (2020).

Google Scholar

Schittenhelm, L., Robertson, J., Pratt, A. G., Hilkens, C. M. & Morrison, V. L. Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint. Rheumatology (Oxford) 60, 1533 (2021).

CAS Article Google Scholar

Torsteinsdttir, I., Arvidson, N. G., Hllgren, N. G. & Hkansson, L. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand. J. Immunol. 50, 433439 (1999).

PubMed Article Google Scholar

Maldonado, A. et al. Decreased effector memory CD45RA+ CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res. Ther. 5, R91 (2003).

PubMed PubMed Central Article Google Scholar

Navarro-Hernndez, R. E. et al. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis. Markers 26, 119126 (2009).

PubMed PubMed Central Article Google Scholar

Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S. & Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 36, 345350 (2007).

CAS PubMed Article Google Scholar

Klimiuk, P. A., Sierakowski, S., Domyslawska, I. & Chwiecko, J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 38, 439444 (2009).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492 (2014).

CAS PubMed Article Google Scholar

Wijbrandts, C. A. & Tak, P. P. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin. Proc. 92, 11291143 (2017).

CAS PubMed Article Google Scholar

Schinnerling, K., Rosas, C., Soto, L., Thomas, R. & Aguilln, J. C. Humanized mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of cell-based therapies. Front. Immunol. 10, 203 (2019).

CAS PubMed PubMed Central Article Google Scholar

Koboziev, I. et al. Use of humanized mice to study the pathogenesis of autoimmune and inflammatory diseases. Inflamm. Bowel Dis. 21, 16521673 (2015).

PubMed Article Google Scholar

Rothbauer, M. et al. Establishment of a human three-dimensional chip-based chondro-synovial co-culture joint model for reciprocal cross-talk studies in arthritis research. Lab Chip 21, 4128. https://doi.org/10.1101/2021.02.19.431936 (2021).

CAS Article PubMed Google Scholar

Damerau, A. & Gaber, T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. Int. J. Mol. Sci. 21, 125 (2020).

Google Scholar

Jorgensen, C. & JSimon, M. In vitro human joint models combining advanced 3D Cell culture and cutting-edge 3D bioprinting technologies. Cells 10, 596 (2021).

PubMed PubMed Central Article Google Scholar

Edilova, M. I., Akram, A. & Abdul-Sater, A. A. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed. J. 44, 172182 (2021).

PubMed Article Google Scholar

Yamin, R. et al. High percentages and activity of synovial fluid NK cells present in patients with advanced stage active rheumatoid arthritis. Sci. Rep. 2019(9), 112 (2019).

Google Scholar

Talbot, J. et al. CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, NJ) 67, 17511759 (2015).

CAS Article Google Scholar

Vasanthi, P., Nalini, G. & Rajasekhar, G. Status of oxidative stress in rheumatoid arthritis. Int. J. Rheum. Dis. 12, 2933 (2009).

PubMed Article Google Scholar

Adhya, S. et al. Serology and immunoglobulin profile in rheumatoid arthritis. Indian J. Pathol. Microbiol. 41, 4347 (1998).

CAS PubMed Google Scholar

Yang, S., Liu, F., Wang, Q. J., Rosenberg, S. A. & Morgan, R. A. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6, e22560 (2011).

ADS CAS PubMed PubMed Central Article Google Scholar

Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A major regulator of leukocyte adhesion. Migr. Signal. Front. Immunol. 10, 1068 (2019).

CAS Article Google Scholar

Khan, S. Q., Khan, I. & Gupta, V. CD11b activity modulates pathogenesis of lupus nephritis. Front. Med. 0, 52 (2018).

Article Google Scholar

Hassan, W. A., Baraka, E. A. & Fouad, N. A. Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status. Egypt. Rheumatol. 37, 165169 (2015).

Article Google Scholar

Luo, Q. et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol. Med. Rep. 17, 32973305 (2018).

CAS PubMed Google Scholar

Liu, Y. et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin. Immunol. 137, 288295 (2010).

CAS PubMed Article Google Scholar

Wan, B. et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, 88448850 (2006).

CAS PubMed Article Google Scholar

Flores-Borja, F., Jury, E. C., Mauri, C. & Ehrenstein, M. R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 105, 1939619401 (2008).

ADS CAS PubMed PubMed Central Article Google Scholar

Gerards, A. H., de Lathouder, S., de Groot, E. R., Dijkmans, B. A. C. & Aarden, L. A. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42, 11891196 (2003).

CAS PubMed Article Google Scholar

Zamora-Atenza, C. et al. Adalimumab regulates intracellular TNF production in patients with rheumatoid arthritis. Arthritis Res. Ther. 16, R153 (2014).

PubMed PubMed Central Article CAS Google Scholar

Schuerwegh, A. J., Van Offel, J. F., Stevens, W. J., Bridts, C. H. & De Clerck, L. S. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford). 42, 541548 (2003).

CAS PubMed Article Google Scholar

Follow this link:
Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific...

In February, UCI launched the Institute for Precision Health, a campus-wide, interdisciplinary endeavor that merges UCIs powerhouse health sciences, engineering, machine learning, artificial intelligence, clinical genomics and data science capabilities. The objective is to identify, create and deliver the most effective health and wellness strategy for each individual person and, in doing so, confront the linked challenges of health equity and the high cost of care.

IPH will bring a multifaceted, integrated approach to what many call the next great advancement in healthcare. The institute is an ecosystem for collaboration across disciplines that comprises seven areas. Along with co-directing the institute, Leslie Thompson Donald Bren and Chancellors Professor in psychiatry & human behavior and neurobiology & behavior co-leads the precision omics section, which generates and translatesgenomic, proteomic and metabolomic research results into clinical applications.

Thompson is among the earliest trailblazers in pursuing personalized treatment strategies for neurodegenerative diseases. Under her co-direction, IPH pushes for understanding the mechanisms for neurodegenerative and other diseases for which there are currently no treatments available. A long-time Anteater, Thompson earned her masters and Ph.D. from UCI.

Why is the Institute for Precision Health so important to you?

So far, precision medicine approaches have mostly commonly been used to treat cancer. Clinicians can utilize data-driven approaches to determine whether a given drug would be expected to work in a specific individual. Ive dedicated my career to studying neurodegenerative diseases like Huntingtons and ALS. With so many of these diseases, including the more common Alzheimers and Parkinsons disease, there is no treatment available that changes the course of the disease, and so many clinical trials have failed to show benefit to patients. Many researchers think the reason there is so little by way of treatment is because we havent been able to fully understand the diseases in individuals that there is not a one-size-fits-all in disease treatment. We need to have ways of understanding diseases in subgroups of patients that incorporates their genetics, environment and other factors that influence health so that we can define diseases better, understand them better and hopefully treat them better. Thats one aspect of IPH that really motivates me.

The capabilities of Institute for Precision Health might allow for better treatments?

Yes. And more. With the resources of IPH, what we can do has broadened significantly. So not only can we use data to understand these diseases and subgroups of patients better, but we can also develop and use state-of-the art analytic tools such as machine learning and artificial intelligence to distinguish individual disease features and or predict the course of disease. The capabilities of IPH through efforts of clinicians who use AI have enabled establishing a scoring system to inform which COVID-19 patients would be predicted to lead to more severe disease and thus greater medical intervention and optimized patient treatment. A critical aspect of healthcare is to understand the needs of the community as well, which is a major component of IPH. A goal is to utilize the infrastructure being developed through IPH to help clinical trials happen much more rapidly with the right cohort of patients, have new ways to evaluate effectiveness of treatments, engage communities and move into a realm of greater partnership with patients and their communities.

The capacity of UCIs Collaboratory the data center of IPH is key?

Yes. It is extremely challenging to put the various forms of data and information for, say, a given person or a given disease together in one place one platform so that researchers, clinicians and other partners can access and work with the data. With UCIs Collaboratory and our platform provider Syntropy, we can gather not only the de-identified health information that is in the medical record but also relevant genomic or other clinical or research data. The goal is to provide broad benefit to UCI and broad engagement across campus. And really beyond the campus.

Does this feel a little like the launch of the first smart phone, where in the beginning we marveled at the cool features and then, almost immediately, we couldnt imagine life without it?

I think so. And, you know, we had so many of the components here at UCI that have been brought together AI tools being developed across campus and the ability to carry out genomics and other omics, and then the efforts of the Collaboratory and the platforms that can house data. But while components were there, they hadnt yet been integrated into that smart phone, so to speak. Now were putting the components together and continually improving capabilities. Our vision is to provide a systematic approach to accomplish things we have never been able to do previously. Even seemingly small things like, how do you track one patient without any identifiers and all the information thats relevant to that patient and their disease? And so much more.

Youve been a part of groundbreaking research and have had so many professional accomplishments. How exciting is IPH in comparison to what youve already done?

Ive been involved in many very meaningful research projects in my career, but to be perfectly honest, this is huge for me, as I feel it ultimately can help the families that I so passionately care about. I see this as my whole career in human genetics and studying human disease has led up to IPH.

The vision is right, the opportunity is here, and UCIs leadership is so supportive of IPH. There is a growing excitement that, yes, we can do something transformative. So, I hope for big things to come out of IPH. Yes, Im all in.

You mentioned that you believe the work IPH does will benefit people beyond the campus. Can you talk a little bit about that?

I think well see further relationships with industry, with community groups, with other research institutions and clinical entities and most importantly with the patients themselves. We are building something that increases our ability to use and integrate data, and that will be useful to so many people and will enable greater health equity.

Do you have any sort of success timeline in mind?

I think most researchers hesitate to think that way because there have been diseases many of us thought wed have a cure for in 10 years, and 30 years later there isnt even an effective treatment. But, that said, I do think that the great thing with this is that many of the components have already been initiated and are working and we have incredible opportunities to now integrate efforts and diverse sets of data to inform patient health and disease. Im confident that there will be immediate goals that IPH will achieve throughout the next year or two. Then there are longer goals that will take five years or 10 years. And even longer-range goals that will be refined as we go.

Do you believe that even in a year or two patients who get care through UCI will feel the effects of IPH?

Yes, absolutely. Patients are already impacted because of IPHs work with COVID-19. One project involving genomics is to try and pinpoint the diagnosis for patients with a muscle weakness disorder that has defied genetic diagnosis. During this next year, well see if we can find genetic causes of that disorder. And through efforts of the AI groups, there will be development of algorithms to assess effectiveness of tools or treatments recently deployed in the hospital. Those are just a couple examples.

Do you see a day where many diseases are diagnosed quicker and more accurately?

Thats certainly one of our goals. IPH researchers have already developed an AI tool to diagnose stroke much more quickly compared to more standard methods. I suspect IPH will be working on many more tools that function in similar ways.

What does UCI bring to the table that maybe some other institutions dont?

One big strength is the support from Chancellor Howard Gillman and other campus leaders. [Vice Chancellor of Health Affairs] Steve Goldstein has led the charge for this institute to become a reality. Also, the fact that we have so much AI, machine learning and artificial intelligence expertise across UCI along with many acclaimed clinicians and medical researchers. Having an academic medical center certainly presents opportunities that researchers elsewhere might not have where they may have great AI expertise but without a medical center. We also perhaps have a unique focus health equity with existing relationships with the community. So, we are distinctive in the fact that we have all the pieces here. UCI is also a uniquely collaborative and nimble institution. We come together and make things happen quickly at UCI. Thats a characteristic of this university that Ive seen play out during my whole career here.

Will there be opportunities to study Orange County to see, as a community, what kind of impact IPH has?

IPH is engaged in this already, and it is a major goal moving forward.

And the way youre able to use data is special?

Yes. Quite often researchers have pulled information from the medical records that is structured data, that has an important role in research that has been facilitated at UCI through efforts of the Collaboratory. However, one of the things that is unusual about the platform is that there will be ways to capture all the structured and unstructured data. This is a big deal.

Everything needs funding, though. Whats happening in that regard?

Yes, great question. Certainly, one of the biggest challenges for any endeavor is raising money. Through support by UCI, we have the funds to launch IPH efforts, but there will need to be extensive fundraising and plenty of grant writing. Philanthropy will be integral to our success and visionaries to relay the excitement about our mission.

If you want to learn more about supporting this or other activities at UCI, please visit the Brilliant Future website athttps://brilliantfuture.uci.edu. Publicly launched on October 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success,health and wellness, research and more. UCI Health Affairs plays a vital role in the success of the campaign. Learn more by visitinghttps://brilliantfuture.uci.edu/uci-health-affairs/.

About UCI Institute for Precision Health: Founded in February 2022, the Institute for Precision Health (IPH) is a multifaceted, integrated ecosystem for collaboration that maximizes the collective knowledge of patient data sets and the power of computer algorithms, predictive modeling and AI. IPH marries UCIs powerhouse health sciences, engineering, machine learning, artificial intelligence, clinical genomics and data science capabilities to deliver the most effective health and wellness strategy for each individual person and, in doing so, confronts the linked challenges of health equity and the high cost of care. IPH is part of UCI Health Affairs, and is co-directed by Tom Andriola, vice chancellor for information, technology and data, and Leslie Thompson, Donald Bren Professor of psychiatry & human behavior and neurobiology & behavior. IPH is a comprised of seven areas: SMART(statistics, machine learning-artificial intelligence), A2IR(applied artificial intelligence research), A3(applied analytics and artificial intelligence), Precision Omics(fosters translation of genomic, proteomic, and metabolomic research findings into clinical applications), Collaboratory for Health & Wellness(providestheecosystem that fosters collaboration across disciplines through the integration of health-related data sources), Deployable Equity(engagescommunity stakeholders and health-equitygroupsto create solutionsthat narrow the disparities gap in the health and wellbeing of underserved and at-risk populations.) and Education and Training (brings data-centric education to students and healthcare practitioners so they can practice at the top of their licenses).

Originally posted here:
Precision health perspectives - UCI News

Strategic partnership leveraging FidoCure's precision medicine platform advances joint vision for providing personalized, accessible veterinary cancer care

AUSTIN, Texas and PALO ALTO, Calif. (PRWEB) July 15, 2022

Thrive Pet Healthcare, a national veterinary hospital network, and https://www.fidocure.com/FidoCure, the leading pet precision health company, today announced a strategic partnership to provide personalized, accessible veterinary cancer care. Thrive Pet Healthcare's nationwide network of over 350 veterinary care clinics will now have access to FidoCure's cutting edge precision medicine platform and unparalleled algorithmic driven diagnostics. By joining forces, these two patient centric companies are poised to deliver groundbreaking pet specialty cancer care at scale and help improve outcomes in pets with cancer.

With roughly six million new cancer diagnoses in dogs each year, approximately one in three dogs will develop cancer during their lifetime. The FidoCure precision medicine platform, developed to address the vast unmet need for better canine cancer care, uses genomic-guided DNA testing to identify genetic mutations that can cause cancer in dogs and matches them to individualized treatment with targeted therapies.

"We are thrilled to partner with FidoCure to offer ground-breaking precision cancer treatment to pet patients in our communities," said Thrive's Chief Medical Officer, Dr. Scott Schatzberg. "Through this powerful partnership, we reinforce our belief in nurturing the animal-human bond and providing exceptional pet healthcare at every stage of a pet's life. Every cancer case is unique, and now a personalized course of treatment is available to every patient within our nationwide network so that they can thrive."

Approximately 3,000 dogs diagnosed with cancer have used the FidoCure Next Generation DNA Sequencing Test, resulting in the largest proprietary canine cancer dataset in the world. Sharing outcomes data, an additional element of this partnership, will significantly expand this dataset. Since humans and dogs are both vulnerable to similar genetic mutations that may cause cancer, the growth of this dataset may help not only advance canine oncology research, but research for humans as well.

"We are delighted to be collaborating with one of the world's most trusted, innovative, and connected pet healthcare networks. This partnership between FidoCure and Thrive Pet Healthcare means that more pet parents, working with Thrive's leading specialty clinicians, will have streamlined access to this cutting-edge cancer care platform," said Christina K. Lopes, co-founder and CEO of FidoCure.

"It is no secret that wide-scale access to veterinary oncology is sorely needed in the veterinary world. This partnership with FidoCure will enable Thrive Pet Healthcare clinicians across the country to better fulfill our mission of providing comprehensive pet care at every stage of life. As a veterinary oncologist, I'm incredibly excited we can more broadly deliver precision medicine to dogs with cancer. It is essential that the scientific advancements available to humans be made available to pets as well, and now we're doing just that with this partnership with FidoCure," said Dr. Mona Rosenberg, Thrive's National Specialty Director of Oncology and Director of Innovation in Clinical Oncology.

About Thrive Pet HealthcareThrive Pet Healthcare is a leading veterinary service network that uniquely delivers a continuum of care to pet families and services to veterinary hospitals. With an industry-first membership program and over 350 acute, primary, and specialty providers, Thrive Pet Healthcare offers personalized, accessible care through every stage of a pet's life and health. The veterinarian-founded organization provides premier benefits for practice staff while elevating privately held veterinary hospitals with innovative service and technology solutions. By focusing on the needs and aspirations of veterinary care providers, Thrive Pet Healthcare is supporting the wellbeing of the industry and raising the national bar for veterinary excellence. To learn more about Thrive Pet Healthcare, please visit http://www.thrivepetcare.com.

About FidoCureFidoCure is the first to bring the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. We are a mission driven company that delivers the most sophisticated diagnostics and creates a tailored treatment plan for each dog. Our flagship product, FidoCure Next Generation DNA Sequencing Test, leverages technologies and therapies approved for human use, with additional data specific to canine cancer. With FidoCure, dogs with cancer receive access to the latest scientific advances in cancer care, from tests to treatment. FidoCure is backed by premier biotech investors including Polaris Ventures, A16Z, YCombinator and Global Brain. Learn more at fidocure.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/2022/MM/prweb18751199.htm

Continued here:
Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga

DUBLIN--(BUSINESS WIRE)--The "Global Compound Management Market Size, Share & Trends Analysis Report by Type (Products, Service), by Sample Type (Chemical Compounds, Bio Samples), by Application, by End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global compound management market size is expected to reach USD 1.49 billion by the end of 2030, expanding at a CAGR of 15.6%.

Growing biopharmaceutical industry and biobanking sector is fueling the market growth. The growth of translational research and personalized medicine is driving the market.

Efficient compound management is tremendously important for the success of drug discovery, where traceability, reliability, speed, and throughput are fundamental. Maintaining samples at the precise temperature, under nitrogen or dry air to prevent fluctuations of stock concentrations, and in a dark environment to avoid photodegradation, can help ensure consistency and longevity of samples.

Compounds of high integrity lead to reliable results while locating drug candidates. Moreover, the collection, storage, and distribution of human biological samples support the development of the R&D industry. In addition, it aids to understand the mechanisms of diseases as well as supports the trend to provide personalized medicines.

Automated storage systems eliminate or reduce the risks and provide reliable and correct environmental conditions to protect samples from precipitation or degradation. A management system like Verso tracks sample data, including location and type, which enables the quick and easy finding of the sample. The fully automated systems improve the process of drug discovery by eliminating error-prone and time-consuming tasks.

North America dominated the market in 2018 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The Asia Pacific market is anticipated to grow fast over the forecast period. This is attributed to ongoing studies in private-public collaborations, drug discovery, and government initiatives in the region.

Compound Management Market Report Highlights

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Competitive Insights

Chapter 3. Compound Management Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement framework

3.4. Market Dynamics

3.4.1. Market driver analysis

3.4.1.1. Growing Drug Research Activities

3.4.1.2. Rising demand for outsourcing compound management services

3.4.1.3. High disease prevalence

3.4.1.4. Expansion of Pharma & Biopharma Research in Emerging Markets

3.4.2. Market restraint analysis

3.4.2.1. Large Capital Investments Required to Establish Compound Management Facilities

3.4.2.2. Quality issues related to compound management by the outsourcing provider

3.5. Compound Management Market Analysis Tools

3.5.1. Industry Analysis-Porter's

3.5.2. PESTEL Analysis

3.5.3. Major Deals & Strategic Alliances Analysis

3.5.4. COVID-19 Impact Analysis

Chapter 4. Compound Management Market: Type Estimates & Trend Analysis

Chapter 5. Compound Management Market: Sample Type Estimates & Trend Analysis

Chapter 6. Compound Management Market: Application Estimates & Trend Analysis

Chapter 7. Compound Management Market: End-Use Estimates & Trend Analysis

Chapter 8. Compound Management Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Profiles

For more information about this report visit https://www.researchandmarkets.com/r/r8bcjv

Go here to read the rest:
The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire

Myriad Genetics, Inc.

Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactions

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight Psychotropic test results from Myriad Genetics, Inc. (NASDAQ: MYGN), according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA).

The PRIME Care (Precision Medicine in Mental Health Care) study is the largest pharmacogenomic (PGx) randomized controlled trial (RCT) ever conducted in mental health. Results of the study were published in the July 2022 issue of the Journal of the American Medical Association (JAMA). The VA independently conducted and funded the study. Myriad Genetics provided the GeneSight tests for the study.

The number of veterans suffering from depression is a serious mental health issue. The PRIME Care study showed that veterans are more likely to achieve depression remission when GeneSight test results are available to inform medication treatment, said Paul J. Diaz, president and CEO, Myriad Genetics. We thank the VA and the investigators for conducting this important research. The results demonstrate how veterans may be helped by clinicians who provide personalized medication treatment and how such treatment can help make a positive impact on their lives, their families lives, and their communities.

In the PRIME Care study, 1,944 veteran patients with MDD received the GeneSight Psychotropic test and were randomized to receive results immediately (pharmacogenomic guided group) or after 24 weeks (usual care group). The study met its objective by achieving statistically significant results on both co-primary endpoints.

One co-primary endpoint showed that over 24 weeks, the pharmacogenomic guided group had a 28% greater likelihood (odds ratio = 1.28, 95% confidence interval 1.05-1.57, p=0.02) of achieving remission from MDD symptoms (defined as a score of five or less on the PHQ-9 depression symptom questionnaire). There were no identified harms from receiving GeneSight testing in the study.

Story continues

The VA PRIME Care Study further reinforces the body of evidence supporting the clinical utility of the GeneSight test as an important tool to inform medication selection in MDD treatment. The study showed a meaningful increase in remission rates for patients whose providers had access to GeneSight test results, said Jay Elliott, vice president, medical affairs of mental health, Myriad Genetics. Remission represents a reduction in symptoms and return to normal or near-normal function, which is considered the optimal treatment goal for both providers and patients.

Another co-primary endpoint showed that patients in the usual care group were approximately two-fold more likely (odds ratio = 2.08, 95% confidence interval 1.52-2.84, p=0.005) to be prescribed medications with substantial predicted gene-drug interactions compared to the pharmacogenomic guided group in the first 30 days after randomization.

Among patients with MDD, provision of pharmacogenomic testing for drug-gene interactions reduced prescription of medications with predicted drug-gene interactions compared with usual care, according to the JAMA publication of the PRIME Care study.

Major Depressive Disorder is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of disability and mortality, according to the VA PRIME Care study website. In fact, the VA estimates that one in eight to 10 veterans has major depression, requiring treatment with psychotherapy and/or antidepressants.1

_______________1 U.S. Department of Veterans Affairs. https://www.research.va.gov/topics/depression.cfm

About the PRIME Care Study

The 24-week PRIME Care study was conducted among 1,944 Veterans who were diagnosed with Major Depressive Disorder at more than 20 VA Medical Centers around the country. The study focused on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat MDD and whether use of the genetic test results improves patient outcomes. Results were calculated at weeks four, eight, 12, 18, and 24.

The study was a two-arm, parallel-groups comparison of patient/provider dyads randomly assigned to receive the results of the GeneSight test at the time the planned treatment is initiated (intervention group) OR results returned after 24 weeks of treatment as usual (delayed results group).

The study incorporated a widely used depression questionnaire, the PHQ-9, to assess severity of depression symptoms. A score of five or less indicates remission of depression symptoms. Patients were required to have a score of nine or more on the PHQ-9 to enroll in the PRIME Care study.

About the GeneSight Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It is designed to provide information that may help avoid the trial-and-error process that often takes place when patients are prescribed certain mental health medications. Tens of thousands of clinicians have ordered the GeneSight test for more than 1.5 million patients in order to receive genetic information that is unique to each patient. GeneSight can be easily ordered by psychiatrists, general practitioners, nurse practitioners and other prescribers via a secure portal. The test can be administered in a home-based kit or a providers office using a simple cheek swab. GeneSight test results are typically provided in two days and supplement other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the Worlds Most Innovative Companies for 2022. For more information, visit http://www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. 2022 Myriad Genetics, Inc. All rights reserved.

Media Contact:Sharvari Dayal(330)-354-7150sharvari.dayal@myriad.com

Investor Contact:Foster Harris(919) 998-8379foster.harris@myriad.com

Continued here:
Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo...

DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.

iPSC Derived Clinical Trials

The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.

The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide.

Key Topics Covered:

1. Report Overview

2. Introduction

3. Current Status of iPSC Industry

3.1 Progress Made in Autologous Cell Therapy Using iPSCs

3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products

3.3 Cost of iPSC Production

3.4 Automation in iPSC Production

3.5 Allogeneic iPSCs Gaining Momentum

3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry

3.7 Major Focus Areas of iPSC Companies

3.8 Commercially Available iPSC-Derived Cell Types

3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays

3.10 Currently Available iPSC Technologies

4. History of Induced Pluripotent Stem Cells (iPSCs)

5. Research Publications on iPSCs

6. iPSC: Patent Landscape Analysis

6.1 Legal Status of iPSC Patents

6.2 Patents by Assignee Organization Type

6.3 Ownership of Patent Families by Assignee Type

6.4 Top Inventors of iPSC Patents

6.5 Top Ten iPSC Inventors

6.6 Most Cited Five iPSC Patents

6.7 Leading Patent Filing Jurisdictions

6.8 Number of Patent Families by Year of Filing

6.9 Patents Representing Different Disorders

6.10 iPSC Patents on Preparation Technologies

6.11 Patents on Cell Types Differentiated from iPSCs

6.12 Patent Application Trends Disease-Specific Technologies

7. iPSC: Clinical Trial Landscape

7.1 Literature and Database Search

7.2 Number of iPSC Clinical Trials by Year

7.3 iPSC Study Designs

7.4 iPSC-Based Clinical Trials With Commercialization Potential

8. Research Funding for iPSCs

8.1 Value of NIH Funding for iPSC Research

8.2 Partial List of NIH Funded iPSC Research Projects in 2022

9. M&A, Collaborations & Funding Activities in iPSC Sector

10. Generation of Induced Pluripotent Stem Cells: An Overview

10.1 Reprogramming Factors

10.2 Integrating iPSC Delivery Methods

10.3 Non-Integrative Delivery Systems

10.4 Comparison of Delivery Methods for Generating iPSCs

10.5 Genome Editing Technologies in iPSC Generation

11. Human iPSC Banking

11.1 Cell Sources for iPSC Banking

11.2 Reprogramming Methods Used in iPSC Banking

11.3 Factors Used in Reprogramming in Different Banks

11.4 Workflow in iPSC Banks

11.5 Existing iPSC Banks

12. Biomedical Applications of iPSCs

12.1 iPSCs in Basic Research

12.2 iPSCs in Drug Discovery

12.3 iPSCs in Toxicology Studies

12.4 iPSCs in Disease Modeling

12.5 iPSCs in Cell-Based Therapies

12.6 Other Novel Applications of iPSCs

12.7 iPSCs in Animal Conservation

13. Market Overview

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mg6l5h

Read more:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -...

MarketsandMarkets Research Pvt. Ltd.

Chicago, July 15, 2022 (GLOBE NEWSWIRE) -- According to the new market research report Research Antibodies and Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) - Global forecast to 2027, published by MarketsandMarkets, the global Research Antibodies and Reagents Market are projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% during the forecast period.

Browse in-depth TOC on Research Antibodies Market and Research Reagents Market244 Tables46 Figures285 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793

The Factors responsible for driving the market are, increasing growth in proteomics and genomics research, growing demand for high-quality antibodies for research reproducibility, and increasing R&D investments in the life sciences industry.

The antibodies segment is expected to grow at the highest CAGR during the forecast period

On the basis of product, the research antibodies and reagents market are segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such as antibodies use for research offer high specificity and selectivity and are used ubiquitously in biochemical and medical research for protein-target identification, regulatory characterization, and discovery, are driving the market.

The primary antibodies segment is accounts for the largest share of the research antibodies and reagents market

On the basis of type, the research reagents market are segmented into primary antibodies and secondary antibodies. In 2021, the primary antibodies segment held the largest share of the global research antibodies market. This segment is witnessing a strong growth due to the use of these antibodies in numerous types of assay formats. Their accuracy in biomarker detection and high specificity and sensitivity are also driving the market.

Story continues

The media & sera reagent is expected to account for the largest share of the market, by type, in 2021

On the Basis of type, the research antibodies and reagents market are segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes, and other reagents. In 2021, the media & sera reagent segment held the largest share of the global research antibodies market. Factors such as use of these components in all types of assays, cell cultures, and techniques is driving the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=94212793

The western blotting segment is expected to account for the largest share of the market, by technology, in 2021

On the basis of technology, the research antibodies and reagents market are segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. The Western blotting segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such as the high adoption of technique in proteomic and genomic research. The results achieved are unique, easy to interpret, and unambiguous, making it suited for evaluating levels of protein expression in cells, protein purification, and comparing the expression of a target protein from various tissues.

The drug development applications segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the research antibodies and reagents market are segmented into proteomics, drug development and Genomics. The drug development segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such increasing demand for personalized medicine and government funding & initiatives in the sector are the key market drivers for this segment.

The pharmaceutical & biotechnology segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the research antibodies and reagents market are segmented into the pharmaceutical & biotechnology companies, academic & research institutions, and Contract Research Organizations. Factors such as the growth of this segment is due to antibodies provide a gold standard for the detection of a biomolecule or a pathway and are even capable of detecting specific changes in potential drug targets. Moreover, highly specific reagents are used to measure pharmacokinetic parameters in the preclinical and clinical development of biological drugs are the key market drivers for this segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793

The APAC market is expected to grow at the highest CAGR during the forecast period

The Asia Pacific research reagents market is expected to grow at the highest CAGR from 2022 to 2027. Factors such as increasing proteomics and genomics research and growing research funding, increasing investments by pharmaceutical and biotechnology companies are driving the market.

Prominent market players in Research Antibodies Market and Research Reagents Market are:

Thermo Fisher Scientific, Inc. (US),

Merck KGaA (Germany),

Abcam plc (UK),

Becton, Dickinson, and Company (US),

Bio-Rad Laboratories (US),

Cell Signaling Technology (US),

F. Hoffmann-La Roche (Switzerland),

Danaher Corporation (US),

Agilent Technologies (US),

PerkinElmer (US),

Lonza (Switzerland),

GenScript (China), and

BioLegend (US).

Browse Adjacent Markets:Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023https://www.marketsandmarkets.com/Market-Reports/custom-antibody-market-164328301.html

Continued here:
Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance

Custom Antibody Market Is Expected To Reach USD 742.27 Million By 2029 At A CAGR Of 10.3 percent.

Maximize Market Research has published a report on theGlobal Custom Antibody Market that provides a detailed analysis for the forecast period of 2022 to 2029.

Custom Antibody Market Scope:

The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industrys history and present situation, as well as expected market size and trends. The research investigates all industry categories, with an emphasis on key companies such as market leaders, followers, and new entrants. The paper includes a full PESTLE analysis for each country. A thorough picture of the competitive landscape of major competitors in the Custom Antibody market by goods and services, revenue, financial situation, portfolio, growth plans, and geographical presence makes the study an investors guide.

Request For Free Sample @https://www.maximizemarketresearch.com/request-sample/34046

Custom Antibody Market Overview:

To accommodate any host needs, customised antibodies can be produced in a mouse, rat, or hamster. Companies offer a wide variety of antibodies based on the needs of the researcher. Polyclonal and monoclonal antibodies, recombinant monoclonal antibodies, hybridoma antibodies, polyclonal recombinant antibodies, and others are available in the market as customised antibodies. For all types and stages of antibody manufacturing, including peptide design, synthesis, carrier protein conjugation, animal immunisation, serum collection, hybridoma fusion, and final antibody purification, businesses are now providing full support services.

Custom Antibody MarketDynamics:

The strong need for research, expanding government assistance, changing illness profiles, developing public-private collaborations, and rising funding activities are all contributing to the expansion of the bespoke antibody market. These aspects also help biotechnology perform better overall. However, depending on the animals used to produce them, the generation of monoclonal and polyclonal antibodies varies. The cost is also influenced by the packages of customised antibodies required for various applications that are provided by various providers, which restricts market expansion.

A key area of research in the healthcare sector, personalised medicine has now permeated mainstream clinical practise and is revolutionising how many diseases are diagnosed, categorised, and treated. These developments are especially noticeable in oncology. The number of personalised medicine medications, therapies, and diagnostic products has grown since 2006, and this trend is anticipated to continue in the upcoming years, according to the Personalized Medicine Coalition study (2020). Additionally, over the past five years, biopharmaceutical companies have almost doubled their R&D expenditures in personalised medicine; over the following five years, this expenditure is predicted to rise by 33 percent. Over the past few years, there has been a surge in the need for protein treatments, such as hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes

Custom Antibody MarketRegional Insights:

A key area of research in the healthcare sector, personalised medicine has now permeated mainstream clinical practise and is revolutionising how many diseases are diagnosed, categorised, and treated. These developments are especially noticeable in oncology. The number of personalised medicine medications, therapies, and diagnostic products has grown since 2006, and this trend is anticipated to continue in the upcoming years, according to the Personalized Medicine Coalition study (2020). Additionally, over the past five years, biopharmaceutical companies have almost doubled their R&D expenditures in personalised medicine; over the following five years, this expenditure is predicted to rise by 35 percent. Over the past few years, there has been a surge in the need for protein treatments, such as hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes.

Custom Antibody MarketSegmentation:

By Services:

By Type:

By Source:

By Research area:

By End-Users:

Custom Antibody Market Key Competitors:

To Get A Copy Of The Sample of the Custom Antibody Market, Click Here @https://www.maximizemarketresearch.com/market-report/global-custom-antibody-market/34046/

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Here is the original post:
Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal

People with extreme nearsightedness, or myopia, may experience myopic macular degeneration (MMD). This condition can lead to a gradual decrease in central vision.

In people with myopia, the distance between the front and back of each eye is greater than average. This increased eyeball size makes it harder to focus on objects in the distance. Some people with this condition may be at greater risk of developing other eye conditions.

This article will review all there is to know about MMD, from signs and symptoms to the latest research.

MMD, also called degenerative myopia, is the leading cause of legal blindness.

The macula is a tiny region located in the center of the retina. When the retina stretches in people with myopia, it can cause the cells in the macula to degenerate.

If damage occurs to cells in the macula, individuals may experience a blind spot in their central vision. The resulting condition is called MMD.

The causes of MMD vary between individuals.

Excessive stretching can change the arrangement of photoreceptors within the eye. This can impact vision even before degeneration begins.

Changes in certain proteins can also occur as a result of eyeball elongation. Atypical collagen proteins, for example, can lead to a weaker eye structure and cause retinal degeneration.

Additionally, researchers believe that inflammatory conditions may contribute to MMD. Chronic inflammation in the eye tissue may further alter eye structure and function.

Although research links macular degeneration and myopia, not all people with myopia will experience macular degeneration.

During the early stages of MMD, people may experience few, if any, symptoms. A blurry spot in the central vision may eventually appear and worsen with time.

Other common symptoms may include:

People who experience unexpected vision changes should consult an eye specialist.

Changes in central vision, gray or blurry spots, or having trouble reading and recognizing people may all indicate MMD.

A specialist will perform a thorough exam and diagnostic tests to determine whether a persons symptoms indicate MMD. They can then discuss the individuals outlook and treatment options.

People with MMD may experience complications. For example, damage to the retina or scarring in the macula tissue may occur. MMD can lead to blindness in severe cases.

Individuals who receive a diagnosis of MMD should consult with a doctor to prevent any potential complications.

Each case of MMD is unique, and only a medical professional can provide an accurate assessment.

Older individuals and people with very severe myopia have a higher chance of developing MMD.

Research from 2022 suggests that genetics and a persons environment can play a role in the development and severity of myopia. A family history of myopia increases an individuals risk of nearsightedness. A person can also inherit changes to genes involved in eyesight.

Additionally, research indicates that spending more time outdoors helps prevent myopia and that modern, urban lifestyles may put individuals at risk of developing myopia and MMD.

There is currently no single cure for MMD. However, several different treatment options may help prevent vision loss among those who develop this condition.

People with MMD usually develop new blood vessels under the retina. These blood vessels can leak and worsen the effects of MMD. One of the most common treatments involves anti-vascular endothelial growth factor (anti-VEGF) injections. Anti-VEGF drugs may reduce new blood vessel growth, improve vision, and slow macular thickening.

Research also indicates that photodynamic therapy may help treat MMD. Read more about laser therapy for macular degeneration here.

A possible surgical procedure is posterior scleral reinforcement (PSR). The main objective of PSR is to slow down axial elongation, which occurs with myopia.

No one treatment protocol is right for everyone. Individuals with MMD should speak with a medical professional to explore the best treatment options for their unique case.

Managing myopia early in life can help reduce the risk of developing MMD. Possible ways to do this include avoiding exposure to screens and emphasizing time spent outdoors.

Other treatments, such as atropine eye drops, can also help decrease myopia progression in children.

In mild cases of myopia, eyeglasses or contact lenses can improve eyesight. People with more severe myopia may elect to have surgery.

Consistent, thorough eye exams can help detect vision changes early. Eye specialists recommend people with severe myopia and MMD have eye exams every year or more frequently if needed.

During an eye exam, a specialist can ensure that the eyes function correctly. They can also monitor any vision changes that develop gradually.

Individuals with severe myopia may be at greater risk for MMD. This condition can lead to vision changes or, in extreme cases, blindness.

Managing myopia early in life can help reduce the risk of developing MMD. Routine eye examinations with a specialist can also help detect vision problems in their earliest stages.

People who experience myopia should work with a medical professional to manage and monitor their condition over time. Consistent medical support can help manage myopia and reduce the long-term effects of MMD.

Read the rest here:

Myopic macular degeneration: What it is, and more - Medical News Today